During the open-label phase , continued BMD increases occurred with long-term denosumab treatment ( 2.2 % lumbar spine , 0.9 % total hip , 1.3 % femoral neck , 1.3 % trochanter , and 0.2 % 1/3 radius ) , resulting in cumulative 24-month gains from baseline of 8.0 % , 3.4 % , 3.4 % , 4.6 % , and 0.7 % , respectively ( all P < .01 ) .